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Background: Allergic asthma is strongly associated with the exposure to house dust mite (HDM) and is characterized
by eosinophilic pulmonary inflammation and airway hyperresponsiveness (AHR). Recently, there is an increased interest
in using dietary oligosaccharides, also known as prebiotics, as a novel strategy to prevent the development of, or reduce,
symptoms of allergy.
Aim: We investigated the preventive capacity of dietary galacto-oligosaccharides (GOS) compared to an intra-airway
therapeutic treatment with budesonide on the development of HDM-induced allergic asthma in mice.
Methods: BALB/c mice were intranasally sensitized with 1 μg HDM on day 0 followed by daily intranasal challenge
with PBS or 10 μg HDM on days 7 to 11. Two weeks prior to the first sensitization and throughout the experiment mice
were fed a control diet or a diet containing 1% GOS. Reference mice were oropharyngeally instilled with budesonide
(500 μg/kg) on days 7, 9, 11, and 13, while being fed the control diet. On day 14, AHR was measured by nebulizing
increasing doses of methacholine into the airways. At the end of the experiment, bronchoalveolar lavage fluid (BALF)
and lungs were collected.
Results: Sensitization and challenge with HDM resulted in AHR. In contrast to budesonide, dietary intervention with 1%
GOS prevented the development of AHR. HDM sensitization and challenge resulted in a significant increase in BALF
leukocytes numbers, which was suppressed by budesonide treatment and dietary intervention with 1% GOS. Moreover,
HDM sensitization and challenge resulted in significantly enhanced concentrations of IL-6, CCL17, IL-33, CCL5 and IL-13
in lung tissue. Both dietary intervention with 1% GOS or budesonide treatment significantly decreased the HDM-
induced increased concentrations of CCL5 and IL-13 in lung tissue, while budesonide also reduced the HDM-enhanced
concentrations of IL-6 and CCL17 in lung tissue.
Conclusion: Not only did dietary intervention with 1% GOS during sensitization and challenge prevent the induction of
airway eosinophilia and Th2-related cytokine and chemokine concentrations in the lung equally effective as budesonide
treatment, it also prevented AHR development in HDM-allergic mice. GOS might be useful for the prevention and/or
treatment of symptoms in asthmatic disease.
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Asthma is a complex disease from which the exact
underlying immunological processes are still not fully
understood [1]. According to the World Health
Organization, 235 million people suffer from asthma
worldwide and it is a common disease among children
[2]. In asthma, the Th2 immune response leads to eo-
sinophilic inflammation in the airways, mucus hyperse-
cretion and airway hyperresponsiveness (AHR) [3].
During sensitization, an antigen activates the airway epi-
thelial cells that in turn, via the release of several chemo-
kines (e.g. CCL5) and cytokines (e.g. IL-33), results in
the activation of innate immune cells such as dendritic
cells (DC). Innate immune cells release Th2 polarizing
cytokines, such as CCL17 and CCL22. In particular, high
concentrations of IL-33 are expressed in epithelial cells
of asthmatic patients [4,5]. Activated DC take up the
allergenic protein and present their peptides to naïve T
cells in draining lymph nodes. The naïve T cells develop
into antigen-specific Th2 cells [6]. Upon subsequent
antigen challenges, antigen-specific Th2 cells are acti-
vated to release IL-4, IL-5 and IL-13, resulting in the de-
velopment of allergen-specific IgE producing plasma
cells and generation and infiltration of eosinophils
[7-11]. Allergen-specific IgE binds to mast cells in the
airways and a second exposure to antigen results in the
degranulation of mast cells. The influx of inflammatory
cells (eosinophils, Th2 cells and mast cells) and produc-
tion of mediators (TNF-a, IL-4, IL-5, IL-6, IL-13, IL-33)
ultimately leads to acute bronchoconstriction, increased
mucus production and AHR [11-13]. Currently, the
treatment of asthma focuses on symptom relief only,
using long-acting beta agonists with or without gluco-
corticosteroids, which is considered highly effective and
safe. However, in many patients, the disease remains
poorly controlled [14]. Long-term treatment with gluco-
corticosteroids can also have considerable side effects,
such as weight gain, muscle weakness, reduced growth
in children and osteoporosis in elderly [15]. In severe
asthma patients long-term treatment can even induce
glucocorticosteroid-resistance [16]. Therefore, novel
preventive and/or therapeutic approaches are needed.
Recent experiments have demonstrated a substantial
influence of the gut microbiota on immune function
beyond the gut. Development of asthma and allergies
might even be due to the changes in gut microbiota
[17-19]. Galacto-oligosaccharides (GOS) are non-digestible
carbohydrates with prebiotic capacity, meaning that they
selectively support growth and/or activity of bifidobacteria
and lactobacilli. These bacteria are associated with a
positive health benefit [17,20]. In addition, in vivo,
in vitro as well as clinical research has shown benefits
of GOS on the digestive and immune health [21-23].
Various animal studies have shown a preventive effectof non-digestible oligosaccharides on allergic diseases.
In food allergic mice, a combination of GOS/long-chain
fructo-oligosaccharides (lcFOS) with Bifidobacterium
breve M-16 V was able to reduce allergic responses
[24]. Van de Pol et al. used the same combination in
patients with asthma and showed an increased peak ex-
piratory flow, but no effect was seen on bronchial in-
flammation [25]. Vos et al. used a combination of GOS,
lcFOS, and pectin-derived acidic oligosaccharides in an
ovalbumine-induced asthma mouse model and showed a
significant suppression of the airway inflammation and
airway hyperreactivity [26]. In a murine OVA-induced
chronic asthma model, Sagar et al. showed a decrease in
pulmonary inflammation and airway remodeling after
long-term treatment with scFOS/lcFOS/AOS in combin-
ation with Bifidobacterium breve [27]. Also treatment with
Bifidobacterium breve alone was as effective as budesonide
in reducing airway remodeling, but not in reducing lung
resistance [28]. The development of allergic asthma is
strongly associated with the exposure to house dust mite
(HDM) [29]. For this reason, this study uses a HDM-
induced allergic asthma model to study the preventive
effect of dietary GOS on the AHR, pulmonary inflamma-
tion and lung cytokine concentrations in comparison with
the therapeutic treatment budesonide.
Materials and methods
Mice
Male BALB/c mice (Charles River, Maastricht, The
Netherlands), 6- to 8-week old (20–25 g), were used in
all experiments. Mice were housed under bio-
contained sterile conditions using HEPA® filtered
isocages® (Tecniplast, Italy). Food and water were provided
ad libitum. All animal experiments were conducted in
compliance with the Guidelines of the Ethical Committee
on the Use of Laboratory Animals of the Utrecht University
(DEC 2013.II.01.003).
HDM murine asthma model
While under isoflurane anaesthesia, BALB/c mice were
intranasally (i.n.) sensitized with 1 μg HDM/40 μL PBS
(Greer Laboratories, Lenoir, USA) on day 0 and challenged
daily on days 7 to 11 with PBS (control, HDM-PBS) or
10 μg HDM/40 μL PBS (HDM-HDM) [30]. From day −14
to 14, mice were fed a control diet (AIN93G, contr) or the
same diet containing 1% v/w GOS (Vivinal® GOS syrup
with approximately 59% galacto-oligosaccharides, 21%
lactose, 19% glucose, and 1% galactose on dry matter
(dry matter of 75%); FrieslandCampina Domo, Borculo,
The Netherlands). Carbohydrates in Vivinal® GOS were
compensated isocalorically in the control diet by means
of cellulose (for GOS), lactose (for lactose), and dextrose
(for glucose). A separate control and HDM-allergic group
were treated with budesonide as a reference treatment
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isoflurane anaesthesia, mice were instilled oropharyngeally,
with budesonide (500 μg/kg, Sigma-Aldrich, Zwijndrecht,
The Netherlands) on days 7, 9 and 11, 6 h prior to the daily
challenge and on day 13, 24 h prior to the assessment of
airway responsiveness to methacholine (Figure 1) [28,31].
Airway responsiveness measurement
Mice were intraperitoneally (i.p.) anaesthetized with a mix
containing Ketamine (Vetoquinol S.A., Lure Cedex, France;
125 mg/kg) and Medetomidine (Pfizer, Capelle a/d Ijssel,
Netherlands; 0.4 mg/kg). Lung function was assessed using
EMKA invasive measurement of dynamic resistance
(EMKA Technologies, Paris, France) in response to in-
creasing doses of methacholine (acetyl-β-methyl-choline
chloride, Sigma-Aldrich, Zwijndrecht, The Netherlands)
(0–25 mg/mL, 10% puff for 10 sec.). Data are presented as
average lung resistance (RL) in cm H2O/mL*sec
−1 [28].
Bronchoalveolar lavage
Mice were killed with an intraperitoneal overdose of
pentobarbital (600 mg/kg, Nembutal™, Ceva Santé Animale,
Naaldwijk, The Netherlands) after the airway responsive-
ness measurement. A small incision was made in the
trachea to insert a cannula. Lungs were lavaged with 1 mL
of pyrogen-free saline (0.9% NaCl, 37°C) supplemented
with protease inhibitor cocktail tablet (Complete Mini,
Roche Diagnostics, Mannheim, Germany). The supernatant
of the first mL was used for cytokine and chemokine meas-
urement. Afterwards, the lungs were lavaged 3 times with
1 mL saline solution (0.9% NaCl, 37°C). The BALF cells
were centrifuged (400 × g, 5 min.) and pellets of the 4
lavages were pooled, resuspended and total numbers of
BAL cells were counted using a Bürker-Türk chamber
(magnification 100x). For differential BAL cell counts, cytos-
pin preparations were made and stained with Diff-Quick
(Merz & Dade A.G., Düdingen, Switzerland). Numbers of
macrophages, lymphocytes, neutrophils and eosinophils
were scored with light microscopy [32].Figure 1 Time schedule of the house dust mite allergic asthma mode
mite (HDM) on day 0 and were challenged on days 7 to 11 i.n. with HDM
day −14 to 14. In a separate set of animals, control mice and HDM-allergic
and 13. All mice were sacrificed on day 14.Preparation of lung homogenates
In brief, lung samples were homogenized in 1% Triton
X100 (Sigma-Aldrich)/PBS containing protease inhibi-
tor (Complete Mini, Roche Diagnostics, Mannheim,
Germany) using a Precellys 24 tissue homogenizer
(Bertin Technologies, France) 3 times for 10 sec. at
6,000 rpm with a minimum of 5 min. cooling period on ice
in between. Homogenates were centrifuged at 14,000 rpm
for 5 min., supernatants collected and stored at −20°C until
further use. The protein concentration of each sample was
assayed using the Pierce BCA protein assay kit standard-
ized to BSA according to the manufacturer's protocol
(Thermo Fisher Scientific, Rockford, IL, USA). The ho-
mogenates were diluted to a final concentration of mg
protein/mL [33,34].Measurement of cytokines
A standard Th1/Th2/Th17 assay (IL-2, −4, −6, −10,
TNF-a, IFNγ; BD Biosciences, Breda, The Netherlands)
was used to determine cytokine concentrations in lung
homogenates according to the manufacturer’s instruc-
tions. Only the IL-6 concentration was assessed since all
other cytokines concentrations were below the detection
limit. IL-33, CCL5 and CCL17 were measured with a
DuoSet ELISA (R&D Systems, Minneapolis, Minnesota,
USA), IL-13 and IL-5 with a Ready-SET-Go!® ELISA
(eBioscience, San Diego, CA, USA). The concentrations
of these cytokines were expressed as pg/mg protein in
lungs and pg/mL in BALF.Statistical analysis
Results are presented as mean ± standard error of mean
(SEM). Data were statistically analyzed using a one-way
ANOVA followed by a Bonferroni’s multiple compari-
sons test. P < 0.05 were considered significant. Statistical
analyses were conducted using GraphPad Prism software
(version 6.04).l. Male BALB/c mice were sensitized intranasally (i.n.) with house dust
or PBS. Mice were fed control diet (AIN93G, contr) or 1% v/w GOS from
mice were oropharyngeally instilled with budesonide on days 7, 9, 11
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Airway hyperresponsiveness was abrogated upon dietary
intervention with 1% GOS in HDM-allergic mice
Airway hyperresponsiveness (AHR) as a measure of
lung function upon HDM exposure was determined in
mice that were fed the control diet or the 1% GOS diet
or those treated with budesonide. The basal airway respon-
siveness (0.70 ± 0.05 cm H2O/(mL/sec) in HDM-PBS-
control group did not differ between the experimental
groups. Moreover, an aerosol with saline (as a control
for methacholine) did not change basal lung resistance
(RL 0.79 ± 0.06 cm H2O/(mL/sec) in HDM-PBS-contr
group. HDM-HDM mice fed the control diet showed a
significant increase in airway hyperresponsiveness
(6.25-25 mg/mL of methacholine) compared to the
HDM-PBS control group. Dietary intervention with 1%
GOS resulted in a significant inhibition of AHR, reducing
it back to control level, in HDM-allergic mice. Treatment
with budesonide did not significantly affect AHR in
HDM-HDM mice (Figure 2).
Dietary intervention with 1% GOS reduced pulmonary
eosinophilic inflammation in the lungs of HDM-allergic
mice
To investigate the inflammatory cell influx into the air-
ways of HDM-allergic mice upon dietary intervention
with 1% GOS or intra-airway treatment with budeso-
nide, BALF was examined (Figure 3A). The total num-
ber of inflammatory cells in the BALF of HDM-HDM
mice fed the control diet was significantly increased
(Figure 3A), which was mainly due to an increase in
the number of eosinophils and macrophages, and there
was also significant increase in the number of lympho-
cytes and neutrophils (Figure 3B-E) compared to the
HDM-PBS control group. Dietary intervention with 1%Figure 2 Airway hyperresponsiveness was abrogated upon dietary in
(RL) in response to increasing doses of methacholine on day 14. HDM-PBS:
and -challenged mice. Contr: control diet; GOS: 1% GOS diet; Bud: budeson
of differences was tested using post hoc Bonferroni’s multiple comparisonsGOS reduced the total number of BALF cells and num-
ber of eosinophils (>57%, P = 0.05) in HDM-allergic
mice (Figure 3B). Treatment with budesonide signifi-
cantly reduced the total number of inflammatory cells
in HDM-allergic mice compared to the HDM-HDM
group fed the control diet (Figure 3A), which was due
to a significant decrease in eosinophil and lymphocyte
numbers (Figure 3B, E).
The effect of 1% GOS on enhanced concentrations of IL-6,
CCL17, IL-33, CCL5 and IL-13 in lungs of HDM-allergic
mice
In order to determine the effect of 1% GOS on pulmon-
ary IL-6 concentrations, lungs were homogenized and
IL-6 concentration was measured in the supernatant.
The lung tissue concentration of IL-6 was significantly
increased in HDM-HDM mice fed the control diet com-
pared to the HDM-PBS control group. After dietary
intervention with 1% GOS, IL-6 concentrations were not
significantly changed in the lung tissue of HDM-allergic
mice compared to controls. Treatment with budesonide
of HDM-HDM mice significantly decreased the IL-6
concentration when compared with non-treated HDM-
allergic mice (Figure 4A). In addition, CCL17 pulmonary
concentrations were significantly increased in HDM-
HDM mice fed the control diet compared to HDM-PBS
control groups. Treatment with budesonide significantly
decreased the CCL17 concentration when compared
with non-treated HDM-allergic mice, 1% GOS showed a
reduction of >20% (Figure 4B). Moreover, the IL-33 con-
centration was significantly increased in supernatants of
HDM-HDM mice compared to the HDM-PBS control
group. In the 1% GOS treated HDM-allergic mice, IL-33
was not changed while it was still enhanced in the
budesonide-treated HDM-allergic group (Figure 4C).tervention with 1% GOS in HDM allergic mice. Airway resistance
HDM-sensitized and PBS-challenged mice, HDM-HDM: HDM-sensitized
ide treatment. Results are shown as mean ± SEM. Statistical significance
test after One-Way ANOVA. *P < 0.05, n = 7–8 mice/group.
Figure 3 Dietary intervention with 1% GOS reduced pulmonary eosinophilic inflammation in the lungs of HDM allergic mice. Infiltration
of inflammatory cells in the BALF of house dust mite allergic mice. HDM-PBS: HDM- sensitized and PBS-challenged mice (white bars), HDM-HDM:
HDM-sensitized and -challenged mice (grey bar). Contr: control diet, GOS: 1% GOS diet, Bud: budesonide treatment. Total BAL cells (A), absolute
number of eosinophils (B), lymphocytes (C), macrophages (D) and neutrophils (E). Results are shown as mean ± SEM. Statistical significance of
differences was tested using post hoc Bonferroni’s multiple comparisons test after One-Way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001,
n = 7–9 mice/group.
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tions were significantly decreased in both HDM-allergic
and control mice when compared to the non-treated
groups, respectively. Treatment with budesonide also
significantly decreased the CCL5 concentrations in the
supernatant of lung tissue obtained from HDM-allergic
and control mice. However, budesonide treatment already
had an effect on CCL5 concentrations in HDM-PBS mice
(Figure 4D). The concentration of theTh2 cytokine IL-13
in the lungs was significantly increased in HDM-HDM
mice fed a control diet compared to the HDM-PBS con-
trol group. Both 1% GOS and budesonide significantly
decreased the HDM allergy-induced increase in IL-13
(Figure 4E). Moreover, IL-13 concentrations in lunghomogenates of HDM-HDM mice positively correlated
with the number of lymphocytes (Figure 4F).
Discussion
The aim of this study was to investigate the prevent-
ive effect of 1% dietary GOS on lung function and
pulmonary inflammation in a murine model of HDM-
induced allergic asthma. As is usually done for poten-
tially new preventive and/or therapeutic agents, we
compared the effectiveness with a golden standard
reference treatment, the corticosteroid budesonide.
To understand the underlying pathophysiology of the
disease, animal models for allergic asthma are used.
Here, a murine model for HDM-allergic asthma was
Figure 4 IL-6, CCL17, IL-33, CCL5 and IL-13 concentrations in lungs of HDM allergic mice. IL-6 (A), CCL17 (B), IL-33 (C), CCL5 (D), and IL-13 (E)
concentrations were measured in supernatant of lung homogenates. Correlation of IL-13 and the number of lymphocytes (F). HDM-PBS:
HDM-sensitized and PBS- challenged mice (white bars), HDM-HDM: HDM-sensitized and -challenged mice (grey bar). Contr: control diet, GOS:
1% GOS diet, Bud: budesonide treatment. Statistical significance of differences was tested using post hoc Bonferroni’s multiple comparisons
test after One-Way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001, n = 6–8 mice/group. Correlation was analyzed using the Spearman correlation test.
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such as HDM-induced AHR, airway inflammation and
pulmonary cytokine release [11,35,36]. Airway respon-
siveness upon methacholine exposure in HDM-allergic
mice was significantly increased when compared to
HDM-PBS control mice. Moreover, total inflammatory
cell numbers were significantly increased in the BALF
of HDM-allergic mice when compared to control mice.
Budesonide treatment showed no significant decrease
on the development of AHR whereas dietary interven-
tion with 1% GOS prevented AHR development in
HDM-allergic mice. However, both interventions sup-
pressed airway inflammation in HDM-allergic mice.
Both 1% GOS and budesonide were effective in the
suppression of airway inflammation and decreased the
number of eosinophils and macrophages. Furthermore,
1% GOS prevented the increase of CCL17 and IL-33
and significantly decreased CCL5 and IL-13 concentra-
tions in the lungs. To our knowledge, this is the first
study to demonstrate that dietary intervention with 1%
GOS during sensitization and challenge is as effective
as treatment with budesonide on allergic HDM asthma
symptoms in a murine model. IL-6 concentrations
have been reported to be increased in serum, BALF
and sputum of asthmatic patients [12,37]. This in-
crease was also observed in the murine model of
HDM-induced allergic asthma. Budesonide, but not 1%GOS, normalized HDM allergy-induced increase of
IL-6 concentrations to the control level. This effect of
budesonide is in agreement with clinical studies which
demonstrate that glucocorticosteroids decrease IL-6
concentrations in BALF in asthmatic patients in asso-
ciation with decreased activation and recruitment of
inflammatory cells in asthma [38]. In our study, bude-
sonide decreased the number of inflammatory cells as
well. Besides being released by macrophages and T
cells, IL-6 is highly expressed by epithelial cells ob-
tained from allergic asthma patients [39]. However,
the exact role of IL-6 in asthma pathology is not fully
understood and has to be further elucidated. In patients
with asthma, CCL17 has been found in increased concen-
trations in serum and BALF [40]. Previously, an important
role for CCR4 and its ligand CCL17 in Th2 T cell recruit-
ment has been demonstrated in asthma [41]. Budesonide
significantly decreased the HDM allergy-induced levels of
CCL17, whereas 1% GOS showed a reduction of >20%.
The latter is in agreement with studies from Leung et al.,
who found higher concentrations of CCL17 in the serum
of non-steroid-treated asthmatic children compared with
steroid-treated asthmatic children [42]. IL-33 is known to
contribute to AHR since animal studies demonstrated that
intranasally administered IL-33 results in an AHR-
association with eosinophilia, goblet cell hyperplasia, and
accumulation of IL-4, −5 and −13 in the lungs [43,44].
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stimulation, is a chemoattractant for Th2 cells and can
activate mast cells to release CXCL8, IL-5, −6, and −13
[45]. Indeed, IL-33 may be involved in human asth-
matic disease, since it is increased in BALF of moderate
asthma patients as compared to mild asthma patients
or controls [46]. Typically the concentration of IL-33 in
the lung tissue obtained in our study was significantly en-
hanced in HDM-allergic and budesonide-treated mice
compared to the control mice. In these budesonide-treated
mice, the AHR was still evident. Indeed, Deckers et al. also
demonstrated that budesonide had no effect on IL-33
concentrations in asthmatic patients [47]. However in
HDM-allergic mice fed 1% GOS the HDM induced in-
crease in IL-33 in lung tissue was prevented. Since IL-33 is
one of the factors contributing to AHR [43,44], this could
relate to the 1% GOS-induced abrogation of the AHR re-
sponse of these mice. CCL5 is produced at high concentra-
tions within the airway epithelium of human asthmatics
and in turn will target eosinophils to the airways [48]. In
this study, both dietary 1% GOS as well as budesonide
treatment showed a significant decrease in CCL5 concen-
trations in lung tissue of HDM-allergic mice. Dampening
of pulmonary CCL5 concentrations could be the mechan-
ism by which GOS and budesonide treatment induces an
abrogation of eosinophil infiltration in the lungs of HDM-
allergic mice. In humans, the release of the Th2 cytokine
IL-5 leads to activation of the eosinophil/basophil lineage.
Increased eosinophil cell influx and AHR are strongly
associated in asthmatic patients and can be provoked
after inhalation of IL-5. However, there are many studies
in humans demonstrating that treatment with anti-IL-5-
specific antibodies reduced the number of eosinophils in
sputum and blood of mild and severe asthmatic patients,
although the AHR was not affected [49]. Thus, inflamma-
tory pathways underlying IL-5 alone are not sufficient for
the development of AHR in allergic asthma. In our study,
IL-5 tended to be increased in the BALF of HDM-allergic
mice whereas this did not occur after dietary intervention
with 1% GOS or treatment with budesonide (Additional
file 1: Figure S1). Indeed, IL-5 in BALF was positively cor-
related with eosinophil numbers (Additional file 1: Figure
S1). The concentration of another Th2 cytokine, IL-13, in
lung tissue was significantly increased in HDM-allergic
mice compared to the control mice. These data are in
agreement with previous studies that show a central role
for IL-13 in generating the murine allergic AHR following
sensitization and challenge of HDM [50]. Many of the
processes involved in allergic asthma can be directed to
IL-13. Besides being secreted by Th2 cells, IL-13 is also
secreted by mast cells and innate lymphoid cells. In the
current study, IL-13 concentrations in lung tissue were
positively correlated with BALF lymphocyte numbers,
suggesting this subset to be an important source of IL-13.IL-13 also triggers macrophage and eosinophil activation
which, in turn, can contribute to AHR [51]. Furthermore,
IL-13 is increased in BALF and bronchial biopsy speci-
mens of asthmatic patients and known to be inhibited by
glucocorticoids [51,52]. Both dietary 1% GOS as well as
budesonide showed a significant decrease in IL-13 con-
centrations in lung homogenates of HDM-allergic mice,
hereby dampening a major contributor to asthmatic in-
flammation. In previous studies, Bifidobacterium breve or
Lactobacillus rhamnosus, either or not combined with
specific oligosaccharides, suppressed airway inflammation
in a murine model for OVA induced chronic asthma
[27,28]. Our studies show similar effects of only GOS in
an acute model for HDM induced asthma. As shown in
earlier studies with dietary oligosaccharides, it is known
that they have a positive effect on the composition of
microbiota [21-23]. A potential mechanism of GOS could
be that by changing the microbiota, immunomodulation
via intestinal epithelial signaling occurs leading to systemic
effects resulting in a decreased HDM immune response,
as has been suggested by several studies [17,20]. In conclu-
sion, in our study budesonide suppressed inflammatory
cell numbers and cytokine concentrations of IL-6, CCL17,
CCL5 and IL-13 in HDM allergic mice. However, budeso-
nide did not modulate the HDM-allergy induced AHR
and increased the pulmonary tissue concentrations of
IL-33. Interestingly, dietary intervention with 1% GOS
prevented the development of AHR and suppressed air-
way eosinophilia in HDM allergic mice. Moreover, 1%
GOS prevented the increase in IL-33 and abrogated the
HDM-induced CCL17, CCL5 and IL-13 release in the
lungs of HDM-allergic mice. Dietary intervention with 1%
GOS may be beneficial in the prevention of HDM-
induced allergic asthma, and may offer a potential novel
strategy with less side effects than current therapeutic
treatments. However, more research is needed to demon-
strate this beneficial effect. In addition, the mechanism of
the immune modulating functions of 1% GOS needs to be
further elucidated, as well as the most effective dose.
Additional file
Additional file 1: Measurement of IL-5 in BALF. IL-5 concentrations
were measured with a Ready-SET-Go!® ELISA (eBioscience, San Diego, CA,
USA). The concentration of this cytokine was expressed as pg/mL. Figure
S1. IL-5 concentrations in the BALF of HDM allergic mice. IL-5 concentration
(A) was measured in the BALF. Correlation of IL-5 and the number of
eosinophils (B). HDM-PBS: HDM-sensitized and PBS-challenged mice
(white bars), HDM-HDM: HDM-sensitized and -challenged mice (grey
bar). Contr: control diet, GOS: 1% GOS diet, Bud: budesonide treatment.
Statistical significance of differences was tested using post hoc Bonferroni’s
multiple comparisons test after One-Way ANOVA. Correlation was analyzed
using the Spearman correlation test.
Abbreviations
AHR: Airway Hyper Responsiveness; BALF: Broncho-Alveolar Lavage Fluid;
GOS: Galacto-oligosaccharide; HDM: House Dust Mite; RL: Lung Resistance.
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